Evidence map›Paper›PMID 42476099›Full record

ArticleNeoplasia (New York, N.Y.)2026

Low dose radiotherapy-induced tumor-preferential antigens enhance antibody-drug conjugate efficacy in solid tumors.

Yun Xing, Yuxuan Yang, Yimin Liu, Teng Yang, Letao Ma, Jiahui Chen, Yang Yang, Yanzhi Xu, Ye Lu, Peng Guo and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neoplasia (New York, N.Y.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yun XingDepartment of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, 310022, China; Key Laboratory of Head and Neck Cancer Translational Research of Zhejiang Province, Hangzhou, 310022, China; Medical School, Faculty of Medicine, Tianjin University, Tianjin, 300072, China.
Yuxuan YangDepartment of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, 310022, China; College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, 310014, China.
Yimin LiuDepartment of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, 310022, China; Hangzhou Institute for Advanced Study, Chinese Academy of Sciences, Hangzhou, Zhejiang, 310024, China.
Teng YangDepartment of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, 310022, China; School of Life Sciences, Fudan University, Shanghai, 200433, China.
Letao MaDepartment of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, 310022, China.
Jiahui ChenDepartment of Gastric Surgery, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, 310022, China.
Yang YangDepartment of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, 310022, China; Department of Thoracic Radiotherapy, Zhejiang Cancer Hospital, Hangzhou, 310022, China.
Yanzhi XuDepartment of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, 310022, China. Electronic address: xuyanzhi@him.cas.cn.
Ye LuDepartment of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, 310022, China. Electronic address: luye@him.cas.cn.
Peng GuoDepartment of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, 310022, China; Medical School, Faculty of Medicine, Tianjin University, Tianjin, 300072, China. Electronic address: guopeng@ucas.ac.cn.
Peijing LiDepartment of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, 310022, China; Key Laboratory of Head and Neck Cancer Translational Research of Zhejiang Province, Hangzhou, 310022, China. Electronic address: lipj@zjcc.org.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antibody-drug conjugate (ADC) efficacy in solid tumors is often limited by low or heterogeneous antigen expression. Here, we investigated low-dose radiotherapy (LDRT) as a noninvasive sensitization strategy to enhance tumor surface antigen expression and improve ADC activity. Transcriptomic profiling and flow cytometry identified ICAM1 as the most strongly radiation-inducible antigen after 2 Gy irradiation, showing an approximately 4-fold increase and exceeding several established ADC targets. Mechanistic studies revealed that radiation-induced reactive oxygen species (ROS) and oxidative stress signaling upregulated ICAM1, enhanced antibody internalization, and improved ICAM1-targeted ADC delivery. In xenograft models, LDRT combined with ICAM1-targeted ADCs achieved >70% tumor growth inhibition with minimal toxicity. Transcriptomic and immunohistochemical (IHC) staining analyses further showed that LDRT induced recruitment of immunosuppressive CCL8

Indexed as

Antigens, NeoplasmImmunoconjugatesNeoplasmsAnimalsCell Line, TumorHumansIntercellular Adhesion Molecule-1MiceRadiotherapy DosageReactive Oxygen SpeciesTumor MicroenvironmentXenograft Model Antitumor AssaysAntigens, NeoplasmImmunoconjugatesIntercellular Adhesion Molecule-1Reactive Oxygen SpeciesAntibody–drug conjugatesBystander killingICAM1 upregulationLow-dose radiotherapyTumor antigen modulationTumor microenvironment

Identifiers

PMID42476099
PMCPMC13392604

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.